Compliance with hormonal treatment for prostate cancer

British Journal of Hospital Medicine

Volumn 55, Issue 6, 1996, Pages 359-366

  Kaisary, A V ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; GONADORELIN;

DRUG TOLERANCE; HUMAN; MALE; ORCHIECTOMY; PATHOLOGY; PATIENT COMPLIANCE; PROSTATE; PROSTATE TUMOR; REVIEW;

ANDROGEN ANTAGONISTS; DRUG TOLERANCE; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; ORCHIECTOMY; PATIENT COMPLIANCE; PROSTATE; PROSTATIC NEOPLASMS;

EID: 0030594209     PISSN: 00071064     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Allvizatos G, Oosterhof GO (1993) Update of hormonal treatment in cancer of the prostate. AntiCancer Drugs 4: 301-9
2. Barradell LB, Faulds D (1994) Cyproterpne. A review of its pharmacology and therapeutic efficacy in prostate cancer. Drues Ageing 5: 59-80
3. Beardon PH, McGilchrist MM, McKendrick AD, MacDevitt DG, MacDonald TM (1993) Primary non-compliance with prescribed medication in primary care. BY Med] 307: 846-8
4. Becker MH (1979) Sociobehavioural determinants of compliance. In: Sackett DL, Haynes RB, eds. Compliance with Therapeutic Regimens. John Hopkins University Press, Baltimore: 40-50
5. Béland G, Elhilali M, Fradet Y et al (1991) Total androgen ablation: Canadian experience. Urol Clin N Amer 18: 75-82
6. Berg JS, Dischler J, Wagner DJ, Raia JJ, PalmerShevlin N (1993) Medication compliance: a healthcare problem. Ann Pharmacother 27: S3-19
7. Bertagna C, de Géry A, Hucher M, François JP, Zamrato I (1994) Efficacy of the combination of nilutamide plus orchidectomy in patients with metastatic prostatic cancer. A meta-analysis of seven randomized double-blind trials (1056 patients). BrJ Urol 73: 396-402
8. Brewster SF, Gillatt DA (1993) Advanced prostate cancer: what's new in hormonal manipulation? BrJ Hoip Med 49: 710-15
9. British Medical Association and the Royal Pharmaceutical Society of Great Britain (1994) British National Formulary. No 28. Pharmaceutical Press, London
10. Brogden RN, Clissold SP (1989) Flutamide, a preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in advanced prostatic cancer. Drugs 38: 185-203
11. Cassileth BR, Spidman EF, Soloway MS et al (1989) Patients' choice of the treatment in Stage D prostate cancer. Urology 33: 57-62
12. Catalona WJ (1994) Management of cancer of the prostate. N EnglJ Med 331: 996-1004
13. Cockshott ID, Cooper KJ, Sweetmore DS, Blacklock NJ, Denis L (1990) The pharmacokinetics of casodex in prostate cancer patients after single and during multiple dosing. Ear Urol 18(SuppI 3): 10-17
14. Cockshott ID, Plummer GF, Cooper KJ, Warwick MJ (1991) The pharmacokinetics of casodex in laboratory animals. Xenobiotica 21: 1347-55
15. Cruickshank JM, McAinsh J (1992) Patient compliance on taking cardiovascular drug therapy. Acta Ther 18: 53-60
16. Daricello G, Serretta V, Pavone-Macaluso M (1987) Flutamide in the treatment of advanced prostate cancer. J Drug Develop l(Suppl 1): 17-22
17. Decensi AU, Boccardo F, Guarneri D et al (1991) Monotherapy with nilutamide, a pure nonsteroidal antiandrogen, in untreated patients with metastatic carcinoma of the prostate.J Urol 146: 377-81
18. Dekker FW, Dielman FE, Kaptein AA, Mulder JD (1993) Compliance with pulmonary medicine in general practice. Eur RespirJ 6: 886-90
19. Delaere KP, van Thillo EL (1991) Flutamide monotherapy as primary treatment in advanced prostatic carcinoma. Semin Oncol 18: 13-18
20. Denis L, Murphy GP (1993) Overview of phase III trials on combined androgen treatment in patients with metastatic prostate cancer. Cancer 72(Suppl): 3888-95
21. Denis LJ, Whelan P, Carneiro de Moura JL et al (1993) Goserelin acetate and flutamide vs bilateral orchiectomy: a phase III EORTC trial. Urology 42:119-30
22. Dijkman GA, Debruyne FM, Fernandez del Moral P et al (1994) A phase III randomized trial comparing the efficacy and safety of the 3-monthly 10.8 mg depot of Zoladex with the monthly 3.6 mg depot in patients with advanced prostate cancer. Eur Urol 26(Suppl): 1-2
23. Di Silveno F, Serio M, D'Eramo G, Sciarra F (1990) Zoladez vs Zoladex plus cyproterone acetate in the treatment of advanced prostatic cancer: a multicenter Italian study. Eur Urol 18(Suppl 3): 54-61
24. Eisenberger MA, Crawford ED, Wolf M et al (1994) Prognostic factors in stage D2 prostate cancer; important implications for future trials: results of a cooperative intergroup study (INT.0036). The National Cancer Institute Intergroup Study INT.0036. Semin Oncol2\: 613-19
25. Fincham JE, Wertheimer AI (1985) Using the health belief model to predict initial drug therapy defaulting. SocSa Med 20: 101-5
26. Goldspeil BR, Kohler DR (1990) Flutamide: an antiandrogen for advanced prostate cancer. Ann Pbarmacotber 24: 616-22
27. Greenberg RN (1984) Overview of patient compliance with medication dosing: a literature review. Clm Ther 6: 592-9
28. Harris MG, Coleman SG, Faulds D, Chrisp P (1993) Nilutamide. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in prostate cancer. Drugs Ageing 3: 9-25
29. Horsmans Y, Lannes D, Larrey D et al (1991) Nilutamide inhibits mephenytoin 4-hydroxylation in untreated male rats and in human liver microsomes. Xenobiotica 21: 1559-70
30. Ice R (1985) Long term compliance. Phys Ther 65: 1832-9
31. Janknegt RA, Abbou CG, Bartoletti R et al (1993) Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial. J Urol 149: 77-83
32. Kaisary AV (1994) Current clinical studies with a new nonsteroidal antiandrogen, casodex. Prostate 5(suppl): 27-33
33. Kaisary AV, Tyrrell CJ, Peeling WB, Griffiths K on behalf of Study Group (1991) Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma. Br J Urol 67: 502-8
34. Kaisary A, Klarskov P, McKillop D (1995) Absence of hepatic enzyme induction in prostate cancer patients receiving casodex (bicalutamide). Eur J Clin Pbarmacol (in press)
35. Kassem NY, Neri RO, Munroe JS (1981) Effect of flutamide, an anti-androgen, on stage D cancer of the prostate (abstract). Clin Pharmacol Ther 29: 256
36. Kennealey GT, Furr BJ (1991) Use of the nonsteroidal anti-androgen casodex in advanced prostatic carcinoma. Ural Clin N Am 18: 99-110
37. Labrie F (1991) Endocrine therapy for prostate cancer. Enaocrinol Metab Clin North Am 20: 845-72
38. Lancet (1989) Androgen blockade and suppression for prostate carcinoma. Lancet i: 1020
39. Lancet (1990) Are you taking the medicine? Lancet i: 262-3
40. Lund F, Rasmussen F (1988) Flutamide vs stilboestrol in the management of advanced prostatic cancer. Br JUrol 61: 140-2
41. Lundgren R (1987) Flutamide as primary treatment for metastatic prostatic cancer. Br] Urol 59: 156-8
42. MacFarlane JR, Tolley DA (1985) Flutamide therapy for advanced prostatic cancer: a phase II study. BrJ Urol 57: 172-4
43. McKillop D, Boyle GW, Cockshott ID, Jones DC, Phillips PJ, Yates RA (1993) Metabolism and enantioselective pharmacokinetics of casodex in man. Xenobiotica 23: 1241-53
44. Ohri SK, Gaer JAR, Keane PF (1991) Hepatocellular carcinoma and treatment with cyproterone acetate. Case report. BrJ Urol 67: 213-21
45. Pavone-Macaluso M, de Voogt HJ, Viggiano G et al (1986) Comparison of diethylstilboestrol, cyproterone acetate and medroxyprogesterone acetate in the treatment of advanced prostatic cancer; final analysis of a randomized phase III trial of the European Organization for Research on the Treatment of Cancer Urological Group.J Urol 136: 624-31
46. Pfitzenmeyer P, Foucher P, Piard F et al (1992) Nilutamide pneumonitis: a report on eight patients. Thorax 47: 622-7
47. Plail R, Hendry W, Demian J et al (1995) Post-marketing surveillance of flutamide in UK hospitals. £rî7roJ27(Supp_ll)
48. Raynaud JP, Moguilewsky M, Tournemine C et al (1985) Pharmacology and clinical studies with anandron. In: Schröder FH, Richards B, eds. EORTC Genitourinary Group, Monograph 2, Part A: Therapeutic Principles in Metastatic Prostatic Cancer. Allan R Liss, Inc: 99-120
49. Rudd P (1992) Maximizing compliance with antihypertensive therapy. Drug Ther 22: 25-32
50. Sacken DL (1979) The magnitude of compliance and noncompliance. In: Sackett DL, Haynes RB, eds. Compliance with Therapeutic Regimens. John Hopkins University Press, Baltimore: 9-25
51. Sau Mei Wong B, Norman DC (1987) Evaluation of a novel medication aid, the calendar Blister-Pak, and its effect on drug compliance in a geriatric outpatient clinic. J Am Geriatr Soc 35: 21-6
52. Schaub AF, Steiner A, Vetter W (1993) Compliance to treatment. Clin Exp Hypertension 15: 1121-30
53. Schellhammer P, Sharifi R, Block N et al (1995) A controlled trial of bicalutamide (casodex) vs flutamide (eulexin), each in combination with luteinising hormone releasing hormone analogue therapy, in patients with advanced prostate cancer. Urology 45:745-52
54. Sogani PC, Vagaiwala MR, Whitmore WF (1984) Experience with flutamide in patients with advanced prostatic cancer without prior endocrine therapy. Cancer 54: 744-50
55. Thorpe SC, Azmatullah S, Fellows GJ, Gingell JC, O'Boyle PJ (1996) A prospective, randomised study to compare goserelin acetate (zoladex®) versus cyproterone acetate (cyprostat®) versus a combination of the two in the treatment of metastatic prostatic carcinoma. Eur Urol 29: 47-54
56. Tyrrell CJ (1992) Casodex: a pure nonsteroidal antiandrogen used as monotherapy in advanced prostate cancer. Prostate 4(suppl): 97-104
57. Varenhorst E (1993) Orchidectomy, GnRH-analogues and anti-androgens in advanced carcinoma ofthe prostate. Laekemedelsverket 3: 89-102
58. Vogelzang NJ, Kennealey GT (1992) Recent developments in endocrine treatment of prostate cancer. Cancer 70(suppl): 966-76
59. Wysowski DK, Freiman JP, Tourtelot JB, Horton ML (1993) Fatal and nonfatal hepatotoxicity associated with flutamide. Ann Int Med 118: 860-4